Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.

Capricor, which was seeking approval of Deramiocel for the treatment of cardiomyopathy associated with DMD, said the FDA issued a so-called complete response letter, indicating the agency won't ...